WO1999027791A1 - Zwitterionic fatty acid compounds for anti-inflamation - Google Patents
Zwitterionic fatty acid compounds for anti-inflamation Download PDFInfo
- Publication number
- WO1999027791A1 WO1999027791A1 PCT/US1998/025244 US9825244W WO9927791A1 WO 1999027791 A1 WO1999027791 A1 WO 1999027791A1 US 9825244 W US9825244 W US 9825244W WO 9927791 A1 WO9927791 A1 WO 9927791A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulfonic acid
- piperazine
- ester
- hydroxyethyl
- hydroxypropane
- Prior art date
Links
- -1 fatty acid compounds Chemical class 0.000 title claims abstract description 16
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract description 6
- 229930195729 fatty acid Natural products 0.000 title abstract description 6
- 239000000194 fatty acid Substances 0.000 title abstract description 6
- 239000007995 HEPES buffer Substances 0.000 claims abstract description 35
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 25
- 150000002148 esters Chemical class 0.000 claims abstract description 21
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 16
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 11
- 230000000699 topical effect Effects 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 9
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 5
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 3
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 229960003080 taurine Drugs 0.000 claims description 9
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 6
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 6
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 5
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 4
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 claims description 3
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007991 ACES buffer Substances 0.000 claims description 3
- 239000008000 CHES buffer Substances 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 3
- 239000007996 HEPPS buffer Substances 0.000 claims description 3
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 claims description 3
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 3
- 239000007993 MOPS buffer Substances 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- VZZMNSJSZXVCCW-UHFFFAOYSA-N 2-amino-n-(4-nitrophenyl)acetamide Chemical compound NCC(=O)NC1=CC=C([N+]([O-])=O)C=C1 VZZMNSJSZXVCCW-UHFFFAOYSA-N 0.000 claims 2
- QDSRPZLVNAXMTL-UHFFFAOYSA-N 2-chloro-1-[4-(4-nitrophenyl)piperazin-1-yl]ethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCN(C(=O)CCl)CC1 QDSRPZLVNAXMTL-UHFFFAOYSA-N 0.000 claims 2
- HSXUNHYXJWDLDK-UHFFFAOYSA-N 2-hydroxypropane-1-sulfonic acid Chemical compound CC(O)CS(O)(=O)=O HSXUNHYXJWDLDK-UHFFFAOYSA-N 0.000 claims 2
- LRTBEWVAOVEHQT-UHFFFAOYSA-N 3-(cyclohexylamino)-1-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)C(O)CCNC1CCCCC1 LRTBEWVAOVEHQT-UHFFFAOYSA-N 0.000 claims 2
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 claims 2
- UIWVQFSAXYWENY-UHFFFAOYSA-N n'-ethylacetohydrazide Chemical compound CCNNC(C)=O UIWVQFSAXYWENY-UHFFFAOYSA-N 0.000 claims 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 239000002585 base Substances 0.000 abstract description 9
- 239000011734 sodium Substances 0.000 abstract description 8
- 150000004665 fatty acids Chemical class 0.000 abstract description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract description 3
- 229920006395 saturated elastomer Polymers 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- 238000011200 topical administration Methods 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 7
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 7
- 229940073769 methyl oleate Drugs 0.000 description 7
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 229940049964 oleate Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102100037611 Lysophospholipase Human genes 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- 108010058864 Phospholipases A2 Proteins 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- RDZTWEVXRGYCFV-UHFFFAOYSA-M sodium 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonate Chemical compound [Na+].OCCN1CCN(CCS([O-])(=O)=O)CC1 RDZTWEVXRGYCFV-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- 206010050031 Muscle strain Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- QSQLTHHMFHEFIY-UHFFFAOYSA-N methyl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC QSQLTHHMFHEFIY-UHFFFAOYSA-N 0.000 description 2
- ZAZKJZBWRNNLDS-UHFFFAOYSA-N methyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC ZAZKJZBWRNNLDS-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- ACERFIHBIWMFOR-UHFFFAOYSA-N 2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-yl)azaniumyl]propane-1-sulfonate Chemical compound OCC(C)(C)NCC(O)CS(O)(=O)=O ACERFIHBIWMFOR-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Definitions
- This invention relates to pharmacologically-active, anti-inflammatory
- invention pertains to novel zwitterionic compounds with pharmacologic activity
- ARA arachidonic acid
- phospholipids including fatty acids, one of which is ARA.
- fatty acids one of which is ARA.
- the first step is the release of ARA from the phospholipid.
- HEPES-ester is thought to be at the level of leukotrienes B4, but it is also possible that it occurs at higher levels in the inflammatory cascade, perhaps at the phospholipase A2 (PPLA2). Inhibition of PPLA2 action would arrest the aforedescribed cascade effect from being initiated.
- taurine synthesis of which occurs in the mammalian liver, and has demonstrated anti-inflammatory activity when administered centrally, but not when administered subcutaneously or interperitoneally.
- N-substituted derivatives of taurine include: 4-(2-Hydroxyethyl)-l -piperazine ethenesulfonic acid; C 8 H 18 N 2 0 4 S, which is commonly identified in the technical literature as HEPES (Merck Index, 12th edition monograph #4687).
- HEPES Merck Index, 12th edition monograph #4687.
- HEPES is available commercially from Angus Chemicals, as the sodium salt or, as the free acid.
- HEPES is a significant agent to reduce cellular inflammation and cellular proliferation.
- delivery systems for the HEPES treatment of inflammation remain to be
- compositions for epidermal penetration, on bruises, muscle strains and sprains are also areas of useful treatment.
- HEPES-containing active ingredient that is not limited to the known subcutaneous injection or IV infusion routes, but may also effective as a topical formulation.
- a still further object of the invention is to provide HEPES esters as a cosmetic formulation ingredient, as a co-emulsifier, usable with topical analgesics.
- Still another object of the invention is in a cosmetic preparation to incorporate an anti-
- the present invention relates to a composition and method for the treatment of inflammatory conditions in mammals, by the topical administration of selected Zwitterionic ester compositions, serving as safe and effective substances.
- Zwitterionic compounds which are preferred include PIPES, BES, POPSO, and preferably HEPES, when esterified, then alone, or in combination with other therapeutic ingredients (see PCT patent document). They are employed by applying to an affected area of the skin, a therapeutically effective amount of at least one skin compatible, Zwitterionic-Ester having the generic
- M is an alkali metal and R is a naturally occurring, straight-chain, saturated or unsaturated, aliphatic acid, the esters of which form fatty acids in nature.
- Zwitterionic-ester has at least one pKa value at 20°C in the range of 6.0- 8.3 to permit its use on human skin, i.e., the ester exists mainly in its dipolar form, in the pH range of 6.0-8.3.
- the isoelectric (ISO) point is the pH at which the net charge on a molecule in solution is 0. At this pH, amino acids exist almost entirely in the Zwitterionic state, i.e., the positive and negative groups are equally ionized. A solution of amino acids at the ISO point exhibits minimum conductivity, osmotic pressures, and viscosity.
- Such dipolar molecules contain, for example, hydroxy groups and amino groups, and
- acid groups like phosphoric, carboxylic or sulfonics acid groups and, generally have
- Preferred aliphatic values for the ester moiety of HEPES ester are n-butanoic; isobutyric, n-valeric, palmitic, and stearic, behenyl, lauric, mynistic, (and their isomers) among the saturated aliphatics; and oleic and linoleic, among the unsaturated aliphatics.
- the invention also provides a pharmaceutical composition for application to human
- esters may be used in the treatment of arthritis, myositis, insect bites, sunburn, psoriasis, atopic dermatitis, and other inflammatory processes of muscle, connective tissue, or
- the effective proportion of the active ingredient is in the range of 1 to 20%, preferably 5 to 10%. In the most preferred composition, the effective proportion lies in the range of 6 to 8. Not every compound falling within the general definition given above, is suitable for topical use in the method of the invention. Some few will prove to be contraindicated. Nevertheless, the exclusion of ineffective active ingredients is a matter well within the competence of the skilled pharmacologist in the conduct of the anti-inflammatory evaluation protocols for disclosed HEPES-esters.
- the topical base is selected from a wide variety of compositions, formulated according to known principals for pharmaceutical purposes. Such compositions include creams, solids, ointments, lotions, and film-forming solutions among others. They may be presented in boxes, jars, or compressible tubes, both collapsible and non-collapsible. The solids may be presented as sticks for rubbing onto the skin. Some of the topical bases may be presented as papers, woven or non-woven fabric pieces, or pads, all being impregnated with composition.
- the invention relates to HEPES derivatives which are pharmacologically active as anti-phospholipase and anti-inflammatory compounds specifically, wherein the active
- ingredients are certain long chain esters of selected zwitterionic compounds, based on an N- substituted taurine, namely aliphatic esters of HEPES.
- novel compounds may exist as at least one of the following five groups: ester, ether, urethane, amide, or urea of all of the following known compounds, and their salt forms.
- Preferred Zwitterionic-esters are prepared from the below listed sulfonic acids. ACES - N-(2-Acetamido) - 2 amino ethane sulfonic acid.
- AMPSO 3-[l,lDimethyl-2 hydroxyethyl amino] -2-hydroxypropane sulfonic acid.
- BES N,N-bis (Hydroxyethyl)-2 aminoethane sulfonic acid.
- DIPSO 3-[N,N-bis (hydroxyl ethyl) amino] -2-hydroxypropane sulfonic acid.
- MOPS - 3-(N-Morpholino) propane sulfonic acid MOPS - 3-(N-Morpholino) propane sulfonic acid.
- the precursor compounds listed above are best known in the literature as biological buffers. Many are commonly used as buffering agents in mammalian cell cultures.
- an alkali metal salt of HEPES is catalytically reacted with an alkyl- substituted, either saturated or unsaturated aliphatic salt, such as methyl oleate, methyl linoleate, methyl palmitate, methyl stearate, methyl myristate, and methyl behenate. They are reacted in equi-molecular amounts carried out either with or without a non-aqueous solvent, such as acetone, and in a temperature range of 0 ° C to (variable) ° C which is between 0°C and the solvent's reflux temperature.
- the purification of the crude ester is carried out by means of crystallization in an organic solvent, dissolved in methanol, and recrystallized.
- HPLC high pressure liquid chromatography
- NMR nuclear magnetic resonance
- Sodium lauryl sulfate solution 0.5% is applied in a patch to four areas on the volar surface forearm. Site one is pretreated with a base formula, site two is pretreated with the base formula plus 10% HEPES ester, while sites three and four are left untreated.
- Sites After 24 hours, the sites are examined, the erythema and edema on sites one and two are recorded by photographs. Site one is treated with the base product, site three is treated with the base product plus 10% HEPES ester, and site two and four are untreated controls. Each treated site is treated four times a day. The observed results are recorded as the percent reduction of erythema and edema at the HEPES ester-treated sites over the base formula and
- the preparation of compound I can be carried out by reacting a fatty acid with HEPES (full compound name) or any one of its salt derivatives.
- HEPES full compound name
- One preferred process route is to react HEPES, sodium salt, with methyl oleate and sodium methoxide as a catalyst.
- the reactions is carried out with an excess of methyl oleate as a solvent. To ensure the completion of the reaction, removal of side product methanol is carried out.
- HEPES ether has the structure:
- HEPES urethane has the structure:
- reaction is carried out by adding isocyanate to the HEPES to form the corresponding urethane below:
- HEPES HEPES-N'-(2-ethane sulfonic acid) I.
- Piperazine-N'-(2-ethane sulfonic acid) I This can be seen as the mono N-substituted analog.
- Another prospective analog is the N-Methylpi ⁇ erazine-N'-(2 ethane sulfonic acid), II, that is readily prepared.
- the piperidine analog, III, of the piperazine ester (Comp I) may be usefully synthesized and evaluated,
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composition and method for treating both superficial and subdermal inflammation is taught by treating an inflamed skin area, muscle, or bone joint, with a therapeutically effective amount of a skin-compatible ester of a zwitterionic aminosulphonic acid (ZASA-Ester) of formula (1) wherein M is an alkali metal, like sodium, and R is a naturally occuring, straight-chain, saturated or unsaturated, aliphatic acid, the esters of which form fatty acids in nature. The most useful of which are the oleic (cis isomer), linoleic, palmitic, and stearic moieties; they occur naturally as glycerides, i.e., esters of glycerol. Also useful are analogs of HEPES like piperazine-N'-(2-ethane sulfonic acid); N-methylpiperazine-N'-(2-ethane sulfonic acid); and the piperiodine analog of the piperazine ester. A pharmacologic composition is also provided which comprises at least one amphoteric (Zwitterionic-ester) with a pharmacologically-acceptable topical carrier or base. Other adjunctive pharmaceutical agents may be included to facilitate other than topical administration.
Description
ZWITTERIONIC FATTY ACID COMPOUNDS FOR ANTIINFLAMATION
FIELD OF THE INVENTION
This invention relates to pharmacologically-active, anti-inflammatory
compounds, and more specifically to long aliphatic chain esters of selected
zwitterionic organic compounds derived from naturally occurring taurine. This
invention pertains to novel zwitterionic compounds with pharmacologic activity
including, but not limited to, the use as an antiinflammatory.
BACKGROUND OF THE INVENTION
Any inflammation that occurs in the mammalian body is the clinical result of a
sequence of events known as the arachidonic acid (ARA) cascade. Cell membranes
consist of phospholipids, including fatty acids, one of which is ARA. In the
inflammation process, the first step is the release of ARA from the phospholipid. The
next step is the conversion of ARA into the specific mediator of inflammation. One
pathway is the cyclooxygenase and the other is called the lipoxygenase pathway.
Cortisone, along with other selected steroidal agents, block both inflammation
pathways by inhibiting ARA release.
The mode of action of HEPES-ester is thought to be at the level of leukotrienes B4, but it is also possible that it occurs at higher levels in the inflammatory cascade, perhaps at the phospholipase A2 (PPLA2). Inhibition of PPLA2 action would arrest the aforedescribed cascade effect from being initiated.
Medical science looks for other biochemicals that lack the recognized side effects of prolonged steroid-based (cortisone) medications. One known human biochemical, taurine, synthesis of which occurs in the mammalian liver, and has demonstrated anti-inflammatory activity when administered centrally, but not when administered subcutaneously or interperitoneally. N-substituted derivatives of taurine include: 4-(2-Hydroxyethyl)-l -piperazine ethenesulfonic acid; C8H18N204S, which is commonly identified in the technical literature as HEPES (Merck Index, 12th edition monograph #4687). HEPES is available commercially from Angus Chemicals, as the sodium salt or, as the free acid. The scientific literature reports that intravenous injection of (14-C) HEPES, or of (3H) taurine, demonstrated rapid clearance, but with a significantly longer half-life compared with taurine. Mahon et al theorized that the greater anti-inflammatory effects of HEPES (sodium salt and the acid) compared with taurine, may be due to its slower systemic distribution or clearance, in vivo. The art suggest that
HEPES is a significant agent to reduce cellular inflammation and cellular proliferation. However, the delivery systems for the HEPES treatment of inflammation remain to be
optimized.
It is thus a principal object of this invention to provide a HEPES-based compound, an ester, and a pharmaceutical formulation including the ester, that is adapted for use in topically applied products to reduce symptoms of skin inflammation, wherein the particular etiology of
the inflammation does not call for, or require, the use of antibiotics or germicidal
compositions. The improved formulations for epidermal penetration, on bruises, muscle strains and sprains are also areas of useful treatment.
It is another object of the invention to combine the HEPES molecule with selected aliphatic acids, as the active ingredient of topical applications, which permit the HEPES moiety to penetrate the skin and so to better effect its anti-inflammatory nature.
It is a further object of the invention to provide a HEPES-containing active ingredient that is not limited to the known subcutaneous injection or IV infusion routes, but may also effective as a topical formulation.
A still further object of the invention is to provide HEPES esters as a cosmetic formulation ingredient, as a co-emulsifier, usable with topical analgesics.
Still another object of the invention is in a cosmetic preparation to incorporate an anti-
skin ageing active ingredient.
These and other objects and benefits of this invention will become apparent from a
study of the following specification.
SUMMARY OF THE INVENTION
The present invention relates to a composition and method for the treatment of inflammatory conditions in mammals, by the topical administration of selected Zwitterionic ester compositions, serving as safe and effective substances. Among useful Zwitterionic compounds which are preferred include PIPES, BES, POPSO, and preferably HEPES, when esterified, then alone, or in combination with other therapeutic ingredients (see PCT patent document). They are employed by applying to an affected area of the skin, a therapeutically effective amount of at least one skin compatible, Zwitterionic-Ester having the generic
formula:
M
wherein M is an alkali metal and R is a naturally occurring, straight-chain, saturated or unsaturated, aliphatic acid, the esters of which form fatty acids in nature.
Preferably, Zwitterionic-ester has at least one pKa value at 20°C in the range of 6.0- 8.3 to permit its use on human skin, i.e., the ester exists mainly in its dipolar form, in the pH range of 6.0-8.3.
The isoelectric (ISO) point is the pH at which the net charge on a molecule in solution is 0. At this pH, amino acids exist almost entirely in the Zwitterionic state, i.e., the positive and negative groups are equally ionized. A solution of amino acids at the ISO point exhibits minimum conductivity, osmotic pressures, and viscosity.
Such dipolar molecules contain, for example, hydroxy groups and amino groups, and
also acid groups, like phosphoric, carboxylic or sulfonics acid groups and, generally have
pKa's in the range of 6.15-8.4.
Preferred aliphatic values for the ester moiety of HEPES ester are n-butanoic; isobutyric, n-valeric, palmitic, and stearic, behenyl, lauric, mynistic, (and their isomers) among the saturated aliphatics; and oleic and linoleic, among the unsaturated aliphatics.
The invention also provides a pharmaceutical composition for application to human
skin in the treatment of inflammation comprising at least one of the above Zwitteronic-esters as the active ingredient, together with a pharmacologically acceptable topical carrier or base. These esters may be used in the treatment of arthritis, myositis, insect bites, sunburn, psoriasis, atopic dermatitis, and other inflammatory processes of muscle, connective tissue, or
skin appendages.
DETAILED DESCRIPTION OF THE INVENTION
The effective proportion of the active ingredient, by weight of the formulation, is in the range of 1 to 20%, preferably 5 to 10%. In the most preferred composition, the effective proportion lies in the range of 6 to 8. Not every compound falling within the general definition given above, is suitable for topical use in the method of the invention. Some few will prove to be contraindicated. Nevertheless, the exclusion of ineffective active ingredients is a matter well within the competence of the skilled pharmacologist in the conduct of the anti-inflammatory evaluation protocols for disclosed HEPES-esters.
The topical base is selected from a wide variety of compositions, formulated according to known principals for pharmaceutical purposes. Such compositions include creams, solids, ointments, lotions, and film-forming solutions among others. They may be presented in boxes, jars, or compressible tubes, both collapsible and non-collapsible. The solids may be presented as sticks for rubbing onto the skin. Some of the topical bases may be presented as papers, woven or non-woven fabric pieces, or pads, all being impregnated with composition.
The invention relates to HEPES derivatives which are pharmacologically active as anti-phospholipase and anti-inflammatory compounds specifically, wherein the active
ingredients are certain long chain esters of selected zwitterionic compounds, based on an N- substituted taurine, namely aliphatic esters of HEPES.
The novel compounds may exist as at least one of the following five groups: ester, ether, urethane, amide, or urea of all of the following known compounds, and their salt forms. Preferred Zwitterionic-esters are prepared from the below listed sulfonic acids. ACES - N-(2-Acetamido) - 2 amino ethane sulfonic acid.
AMPSO - 3-[l,lDimethyl-2 hydroxyethyl amino] -2-hydroxypropane sulfonic acid. BES - N,N-bis (Hydroxyethyl)-2 aminoethane sulfonic acid.
DIPSO - 3-[N,N-bis (hydroxyl ethyl) amino] -2-hydroxypropane sulfonic acid.
CAPS - 3-(cyclohexylamino)-l -propane sulfonic acid.
CAPSO - 3-(cyclohexylamino)-l -propane sulfonic acid.
CHES - 2-(N-cyclohexylamino) ethane sulfonic acid.
HEPPS - N-(2-hydroxy ethyl) piperazine-N'-3-propane sulfonic acid.
HEPES - N-(2-hydroxy ethyl) piperazine-N'-(2-propane sulfonic acid).
HEPPSO - N-(2-hydroxy ethyl) piperazine-N'-2-hydroxypropane sulfonic acid.
MES - 2-(N-Morpholino) ethane sulfonic acid.
MOPS - 3-(N-Morpholino) propane sulfonic acid.
MOPSO - 3-(N-Morpholino) -2 hydroxy propane sulfonic acid.
PIPES - Piperazine - N, N'-bis (2 ethane sulfonic acid).
New Mono PIPES - Piperazine - N'-(2 ethane sulfonic acid).
POPSO - Piperazine - N, N'-bis (2 -hydroxy propane sulfonic acid).
TAPS - 3 -[N-tris- (hydroxy methyl) methyl amine] -2 -hydroxy propane sulfonic acid.
TES - N-tris-(hydroxy methyl)-methyl-2-amine ethane sulfonic acid.
The precursor compounds listed above are best known in the literature as biological buffers. Many are commonly used as buffering agents in mammalian cell cultures.
Manufacturers of these compounds include Angus Chemicals, SIGMA, and British Drug
House.
SYNTHESIS OF HEPES ESTERS
Generally, an alkali metal salt of HEPES is catalytically reacted with an alkyl- substituted, either saturated or unsaturated aliphatic salt, such as methyl oleate, methyl linoleate, methyl palmitate, methyl stearate, methyl myristate, and methyl behenate. They are reacted in equi-molecular amounts carried out either with or without a non-aqueous solvent,
such as acetone, and in a temperature range of 0°C to (variable)°C which is between 0°C and the solvent's reflux temperature. The purification of the crude ester is carried out by means of crystallization in an organic solvent, dissolved in methanol, and recrystallized. As to analytical methodology, preparative high pressure liquid chromatography (HPLC) is followed by TLC, HPLC, and nuclear magnetic resonance (NMR). Potentiometric titration and bromic titradon are done across the double bond to establish identity and purity. The HPLC device is equipped with a variable length, ultraviolet detector.
PROTOCOL TO EVALUATE CANDIDATE FORMULATIONS FOR SUPPRESSION OF INDUCED SKIN INFLAMMATIONS
Sodium lauryl sulfate solution 0.5% is applied in a patch to four areas on the volar surface forearm. Site one is pretreated with a base formula, site two is pretreated with the base formula plus 10% HEPES ester, while sites three and four are left untreated.
After 24 hours, the sites are examined, the erythema and edema on sites one and two are recorded by photographs. Site one is treated with the base product, site three is treated with the base product plus 10% HEPES ester, and site two and four are untreated controls. Each treated site is treated four times a day. The observed results are recorded as the percent reduction of erythema and edema at the HEPES ester-treated sites over the base formula and
two control treated sites.
WORKING EXAMPLE 1
Active ingredients synthesis procedure (that effect the HEPES -oleate synthesis)
Preparation of HEPES (C8H18N204S) -Oleate Ester I
(CH3(CH2)7 CH=CH(CH2)7(=0)O2 (CH2)2-N N (CH2)2 S03M
The preparation of Compound I is characterized by catalytically reacting 4-(2-
Hydroxyethyl) piperazine- 1- eth.anesulfonic acid, with salts, like methyl oleate, C17H33C02CH3,
in equimolar amounts. The reaction can be carried out in a non-aqueaous solvent. Sodium methoxide is a useful catalyst. The reaction temperature may vary between 0°C and the solvent reflux temperature. The purification of the compound is carried out by means of crystallization in a solvent such as acetone. I. THE ESTERS.
Methyl oleate HEPES Na+Na methoxide→HEPES oleate+Methyl alcohol
HEPES Na oleate
HEPES ESTERS GENERIC FORMULA
R-CO-(CH2)2 N N (CH2)2 S03 M
II | ^
O H
The preparation of compound I can be carried out by reacting a fatty acid with HEPES (full compound name) or any one of its salt derivatives. One preferred process route is to react HEPES, sodium salt, with methyl oleate and sodium methoxide as a catalyst.
O HO
H3 C(CH2)7 -CH=CH-(CH2)7 C-R + (CH2)2 N N (CH2)2 S03 Na
(R=OCH3)
H3 C(CH2)7 -CH=CH-(CH2)7 (CH2)2 S03 Na
The reactions is carried out with an excess of methyl oleate as a solvent. To ensure the completion of the reaction, removal of side product methanol is carried out.
Preparation of the HEPES oleate; sodium salt 4-(2-Hydroxyethyl) piperazine- 1 - ethanesulfonic acid, sodium salt, is slowly added to a stirring flask of methyl oleate in equal
molar equivalents. The mixture is stirred at room temperature for 15 minutes. Then a catalytic quantity of sodium methoxide is slowly added to the stirring mixture. The reaction mix is stirred for less than five minutes. The reaction mix is then slurried in acetone, then isolated and dried, affording greater than an 80% yield of the title oleate as a white to off-white solid, to wit:
In a 500 ml 3 neck flask, 114 gms of methyl oleate is added with 100 gms of HEPES, sodium salt (source: Angus Chemical); while stirring, the mixed is warmed to 27-30°C. Once at 27-30°C, 0.4 gms of the sodium methoxide catalyst is added. A mild exotherm is observed, and the contents are slowly heated to 45-50°C. Once at 45-50°C, vacuum is applied to remove methanol to ensure reaction completion.
After two hours at 45-50°C and under vacuum, the reaction is complete. The vacuum is removed and acetone is added. With the reaction mix in acetone solution it is slowly cooled to 0-5 °C over two hours, and stirred for an additional six hours before isolating the HEPES oleate, sodium salt, in a filter funnel. The white to off-white solid product is then placed in a vacuum oven at 50°C at 28" of vacuum for six hours to remove any remaining acetone or methanol. A greater than 80% yield is obtained.
WORKING EXAMPLE 2 II. HEPES ether has the structure:
HO(CH,)0 (CH,)2 N N (CH2) S03 λ /
H
HEPES, Na salt, is reacted with ethylene oxide to form the ether of the below generic structural formula:
HO-CH,-0-(CH2)2- N N (CH,)2 S03
/ H
HEPES Ether Working Example 3
III. HEPES urethane has the structure:
+ / \
R-N-C-O (CH2)2 N N (CH2)2 S03
H O H
The reaction is carried out by adding isocyanate to the HEPES to form the corresponding urethane below:
HO (CH2)2 N N-(CH2)2 SO~+C6H5N=C=0
H
I o ll V \
C6H5-N-C-0-(CH2)2 N K-(CH2)2 S03
H HEPES URETHANE
WORKING EXAMPLE 4
Certain other analogs and derivatives of HEPES can be synthesized, such as Piperazine-N'-(2-ethane sulfonic acid) I. This can be seen as the mono N-substituted analog. Another prospective analog is the N-Methylpiρerazine-N'-(2 ethane sulfonic acid), II, that is readily prepared. Also, the piperidine analog, III, of the piperazine ester (Comp I) may be
usefully synthesized and evaluated,
Na
Δ Aqueous / \
MeN . N + BrCH2CH2S03Na >MeN N(CH2)2S03 Na III
Claims
1. A method for treating inflammation, comprising applying to an inflamed area a therapeutically effective amount of a skin-compatible ester of a zwitterionic aminosulphonic acid of the formula
M 
wherein M is an alkali metal and R is a straight chain aliphatic acid moiety.
2. A method according to claim 1 , wherein R is selected from the group consisting of n-butanoic, isobutyric, n-valeric, palmitic, stearic, behenyl, lauric, myristic, oleic and linoleic acids.
3. A method according to claim 1 , wherein the ester has at least one pKa value at
20┬░C in the range of 6.0-8.3.
4. A method according to claim 1 , wherein the inflammation associated with arthritis, myositis, insect bites, sunburn, psoriasis, or atopic dermatitis.
5. A method according to claim 1, wherein the method is for treating muscle inflammation.
6. A method according to claim 1. wherein the method is for treating skin inflammation.
7. A method according to claim 1 , wherein the ester is applied in a
pharmacologically acceptable topical carrier.
8. A method according to claim 1 , wherein the pharmacologically acceptable topical carrier is in solid or lotion form.
9. A method for treating inflammation, comprising applying to an inflamed area a
therapeutically effective amount of a skin-compatible component comprising an ester, ether,
urethane, amide or urea of at least one compound selected from the group consisting of
N-(2-acetamido)-2-aminoethane sulfonic acid (ACES),
3-[l ,l -dimethyl-2-hydroxyethyl amino]-2-hydroxypropane sulfonic acid (AMPSO),
N,N-bis (hydroxyethyl)-2-aminoethane sulfonic acid (BES),
3-[N,N-bis (hydroxyethyl) amino]-2-hydroxypropane sulfonic acid (DIPSO).
3-(cyclohexylamino)- l -propane sulfonic acid (CAPS),
3-(cyclohexylamino)-l-hydroxypropane sulfonic acid (CAPSO),
2-(N-cyclohexylamino) ethane sulfonic acid (CHES),
N-(2-hydroxyethyl) piperazine-N' -3 -propane sulfonic acid (HEPPS), N-(2-hydroxyethyl) piperazine-N'-(2-propane sulfonic acid) (HEPES),
N-(2-hydroxyethyl) piperazine-N'-2-hydroxypropane sulfonic acid (HEPPSO),
2-(N-morpholino) ethane sulfonic acid (MES), 3-(N-morpholino) propane sulfonic acid (MOPS), 3-(N-morpholino)-2-hydroxypropane sulfonic acid (MOPSO),
piperazine-N.N'-bis (2-ethane sulfonic acid) (PIPES),
piperazine-N'-(2-ethane sulfonic acid) (mono PIPES),
piperaz╬╣ne-N.N"-bis (2-hydroxypropane sulfonic acid) (POPES), 3-[N-tris-(hydroxymethyl) methyl amine]-2-hydroxypropane sulfonic acid (TAPS), and
N-tris-(hydroxymethyl) methyl-2-amine ethane sulfonic acid (TES).
10. A method according to claim 9, wherein the skin-compatible component has at
least one pKa value at 20┬░C in the range of 6.0-8.3.
1 1. A method according to claim 9, wherein the inflammation associated with
arthritis, myositis, insect bites, sunburn, psoriasis, or atopic dermatitis.
12. A method according to claim 9, wherein the method is for treating muscle
inflammation.
13. A method according to claim 9, wherein the method is for treating skin
inflammation.
14. A method according to claim 9. wherein the ester is applied in a
pharmacologically acceptable topical carrier.
15. A method according to claim 9, wherein the pharmacologically acceptable topical carrier is in solid or lotion form.
16. A composition for treating inflammation, comprising a therapeutically effective amount of a skin-compatible ester of a zwitterionic aminosulphonic acid of the formula
/ \
RO-CH2-CH2-N N-CH2-CH2S03 M
H ^ ' wherein M is an alkali metal and R is a straight chain aliphatic acid moiety.
17. A composition for treating inflammation, comprising a therapeutically effective amount of a skin-compatible component comprising an ester, ether, urethane, amide or urea of at least one compound selected from the group consisting of N-(2-acetamido)-2-aminoethane sulfonic acid (ACES),
3-[l,l-dimethyl-2-hydroxyethyl amino]-2-hydroxypropane sulfonic acid (AMPSO), N,N-bis (hydroxyethyl)-2-aminoethane sulfonic acid (BES),
3-[N,N-bis (hydroxyethyl) amino]-2-hydroxypropane sulfonic acid (DIPSO),
3 -(cyclohexylamino)-l -propane sulfonic acid (CAPS),
3-(cyclohexylamino)-l-hydroxypropane sulfonic acid (CAPSO),
2-(N-cyclohexylamino) ethane sulfonic acid (CHES),
N-(2-hydroxyethyl) piperazine-N'-3-propane sulfonic acid (HEPPS).
N-(2-hydroxyethyl) piperazine-N'-(2-propane sulfonic acid) (HEPES),
N-(2-hydroxyethyl) piperazine-N'-2-hydroxypropane sulfonic acid (HEPPSO), 2-(N-moφholino) ethane sulfonic acid (MES), 3-(N-morpholino) propane sulfonic acid (MOPS), 3-(N-morpholino)-2-hydroxypropane sulfonic acid (MOPSO), piperazine-N,N'-bis (2-ethane sulfonic acid) (PIPES), piperazine-N'-(2-ethane sulfonic acid) (mono PIPES), piperazine-N.N'-bis (2-hydroxypropane sulfonic acid) (POPES), 3-[N-tris-(hydroxymethyl) methyl amine]-2-hydroxypropane sulfonic acid (TAPS), and N-tris-(hydroxymethyl) methyl-2-amine ethane sulfonic acid (TES).
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002311796A CA2311796A1 (en) | 1997-11-28 | 1998-11-25 | Zwitterionic fatty acid compounds for anti-inflammation |
| US09/555,278 US6306858B1 (en) | 1997-11-28 | 1998-11-25 | Zwitterionic fatty acid compounds for anti-inflammation |
| AU16084/99A AU1608499A (en) | 1997-11-28 | 1998-11-25 | Zwitterionic fatty acid compounds for anti-inflamation |
| EP98960500A EP1033913A1 (en) | 1997-11-28 | 1998-11-25 | Zwitterionic fatty acid compounds for anti-inflamation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6691897P | 1997-11-28 | 1997-11-28 | |
| US60/066,918 | 1997-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999027791A1 true WO1999027791A1 (en) | 1999-06-10 |
Family
ID=22072558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/025244 WO1999027791A1 (en) | 1997-11-28 | 1998-11-25 | Zwitterionic fatty acid compounds for anti-inflamation |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6306858B1 (en) |
| EP (1) | EP1033913A1 (en) |
| AU (1) | AU1608499A (en) |
| CA (1) | CA2311796A1 (en) |
| WO (1) | WO1999027791A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0904073A1 (en) * | 1996-02-13 | 1999-03-31 | T. Ronald Theodore | Zwitterionic compositions and methods as biological response modifiers |
| WO2002039975A1 (en) * | 2000-11-17 | 2002-05-23 | L'oreal | Use of at least a sulphonic amino derivative in a composition promoting skin peeling |
| FR2864784A1 (en) * | 2004-01-06 | 2005-07-08 | Oreal | COSMETIC COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND AN AMINO-SULFONIC COMPOUND |
| WO2007100006A1 (en) * | 2006-03-03 | 2007-09-07 | Shiseido Company, Ltd. | Wrinkle preventive/remedy |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4387802B2 (en) * | 2002-03-08 | 2009-12-24 | ビーエーエスエフ ソシエタス・ヨーロピア | Bactericidal mixture based on prothioconazole and containing an insecticide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4544656A (en) * | 1982-08-17 | 1985-10-01 | Sullivan Donncha O | Pharmaceutical composition and method of treating psoriasis |
| US5248680A (en) * | 1990-07-30 | 1993-09-28 | Bloomfield D.A. | Zwitterionic compounds and their n-halo derivatives for use in the treatment of clinical conditions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716959A (en) | 1996-02-13 | 1998-02-10 | T. Ronald Theodore | Method of treating disease with piperazine zwitterion compounds |
-
1998
- 1998-11-25 AU AU16084/99A patent/AU1608499A/en not_active Abandoned
- 1998-11-25 WO PCT/US1998/025244 patent/WO1999027791A1/en not_active Application Discontinuation
- 1998-11-25 CA CA002311796A patent/CA2311796A1/en not_active Abandoned
- 1998-11-25 US US09/555,278 patent/US6306858B1/en not_active Expired - Fee Related
- 1998-11-25 EP EP98960500A patent/EP1033913A1/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4544656A (en) * | 1982-08-17 | 1985-10-01 | Sullivan Donncha O | Pharmaceutical composition and method of treating psoriasis |
| US5248680A (en) * | 1990-07-30 | 1993-09-28 | Bloomfield D.A. | Zwitterionic compounds and their n-halo derivatives for use in the treatment of clinical conditions |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0904073A1 (en) * | 1996-02-13 | 1999-03-31 | T. Ronald Theodore | Zwitterionic compositions and methods as biological response modifiers |
| EP0904073A4 (en) * | 1996-02-13 | 2001-04-04 | T Ronald Theodore | Zwitterionic compositions and methods as biological response modifiers |
| WO2002039975A1 (en) * | 2000-11-17 | 2002-05-23 | L'oreal | Use of at least a sulphonic amino derivative in a composition promoting skin peeling |
| FR2816837A1 (en) * | 2000-11-17 | 2002-05-24 | Oreal | Use of amino sulfonic acid derivatives in cosmetic compositions to aid desquamation, counteract aging and stimulate epidermal renewal |
| FR2864784A1 (en) * | 2004-01-06 | 2005-07-08 | Oreal | COSMETIC COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND AN AMINO-SULFONIC COMPOUND |
| EP1552816A1 (en) * | 2004-01-06 | 2005-07-13 | L'oreal | Cosmetic composition comprising an organosiloxane elastomer and a amino-sulfonic compound. |
| WO2007100006A1 (en) * | 2006-03-03 | 2007-09-07 | Shiseido Company, Ltd. | Wrinkle preventive/remedy |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1033913A1 (en) | 2000-09-13 |
| AU1608499A (en) | 1999-06-16 |
| CA2311796A1 (en) | 1999-06-10 |
| US6306858B1 (en) | 2001-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2137755C1 (en) | Conjugates: therapeutic compound-fatty acid | |
| US6114337A (en) | Zwitteronic-fatty acid compounds having anti-inflammatory properties | |
| US20100113601A1 (en) | Method for decreasing sebum production | |
| EP0291159A2 (en) | Aminosalicylic-acid derivatives for the treatment of psoriasis | |
| EP0574255B1 (en) | New derivatives of non-steroidal anti-inflammatory, analgesic and/or antipyretic substances, their use and pharmaceutical formulations containing them | |
| JPH04502918A (en) | Novel hydroxyl or NH acidic group-containing prodrug derivatives of biologically active agents | |
| US5958911A (en) | Method of relieving inflammation by using 5-alkylsulfonylsalicylanilides | |
| RU2753490C2 (en) | Ror-gamma modulators | |
| JP3458041B2 (en) | Anti-aging agent and skin cosmetic | |
| DE69733778T2 (en) | Long-chain alcohols, alkanes, fatty acids, and amides as viral inhibitors | |
| US6306858B1 (en) | Zwitterionic fatty acid compounds for anti-inflammation | |
| KR100454757B1 (en) | Anti-aging Agents and Skin Cosmetics | |
| KR100297061B1 (en) | Polyethoxylated retinamide derivatives and process for preparing the same | |
| AU618759B2 (en) | Pharmaceutical compositions for the treatment of psoriasis | |
| US6448251B1 (en) | Zwitterionic-fatty acid compounds having anti-inflammatory properties | |
| CZ102797A3 (en) | Compounds based on omega-amino acids, process of their preparation, their use as transdermal penetration accelerators and transdermal penetration accelerators formed by these compounds | |
| KR20130037405A (en) | Novel adamatan derivative compound | |
| JPH0692293B2 (en) | External skin preparation | |
| US6331570B1 (en) | Active enantiomer of RARγ-specific agonist | |
| US20040171676A1 (en) | L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same | |
| JPH07206624A (en) | Skin external agent | |
| SU750983A1 (en) | N-[4-(3,3-dimethyltriazeno)phenylsulfonyl] lauroylamide displaying anti-inflammatory activity | |
| SK103496A3 (en) | 2-(4-methoxyphenoxy)-3-pyridineamine, its pharmaceutical preparations and their use in therapy | |
| IE50921B1 (en) | Pharmaceutical preparations for topical application which contain salts of alkanecarboxylic acids,novel carboxylic acid salts and the production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| ENP | Entry into the national phase |
Ref document number: 2311796 Country of ref document: CA Ref country code: CA Ref document number: 2311796 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09555278 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 522795 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998960500 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1998960500 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998960500 Country of ref document: EP |